Publications by authors named "David Amantini"

Claim this Profile
D
Discovery of GLPG4471, a potent and selective IRAK4 inhibitor for the treatment of inflammatory and autoimmune diseases.
Oscar Mammoliti, Florence Bonnaterre, Gregory Newsome, Rhalid Akkari, Miriam López-Ramos, David Amantini

Bioorg Med Chem Lett· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure activity relationship exploration of imidazo[1,2-a]pyridine series to reverse isoform selectivity and identify potent SIK1 selective inhibitors.
Christophe Peixoto, Elsa De Lemos, Laëtitia Cherel, Gregory Newsome, Aurelie Dos Santos, David Amantini

Bioorg Med Chem Lett· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Activity Relationship Guided Scaffold Hopping Resulted in the Identification of GLPG4970, a Highly Potent Dual SIK2/SIK3 Inhibitor.
Hans Kelgtermans, Maxim De Wachter, Stijn Heyndrickx, Sandy El Bkassiny, Tatiana Lacarriere, David Amantini

J Med Chem· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of a potent and selective dual JAK1/TYK2 inhibitor.
Oscar Mammoliti, Christel Menet, Céline Cottereaux, Javier Blanc, Ann De Blieck, David Amantini

Bioorg Med Chem· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases.
Oscar Mammoliti, Sébastien Martina, Pieter Claes, Ghjuvanni Coti, Roland Blanque, David Amantini

J Med Chem· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Clinical Candidate GLPG3970: A Potent and Selective Dual SIK2/SIK3 Inhibitor for the Treatment of Autoimmune and Inflammatory Diseases.
Christophe Peixoto, Agnes Joncour, Taouès Temal-Laib, Amynata Tirera, Aurélie Dos Santos, David Amantini

J Med Chem· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of Selectivity and Pharmacokinetic Properties of Salt-Inducible Kinase Inhibitors that Led to the Discovery of Pan-SIK Inhibitor GLPG3312.
Taouès Temal-Laib, Christophe Peixoto, Nicolas Desroy, Elsa De Lemos, Florence Bonnaterre, David Amantini

J Med Chem· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Pharmacokinetics, and Pharmacodynamics of the ADAMTS-5 Inhibitor GLPG1972/S201086 in Healthy Volunteers and Participants With Osteoarthritis of the Knee or Hip.
Ellen van der Aar, Henri Deckx, Sonia Dupont, Ann Fieuw, Stephane Delage, David Amantini

Clin Pharmacol Drug Dev· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of GLPG1972/S201086, a Potent, Selective, and Orally Bioavailable ADAMTS-5 Inhibitor for the Treatment of Osteoarthritis.
Franck Brebion, Romain Gosmini, Pierre Deprez, Marie Varin, Christophe Peixoto, David Amantini

J Med Chem· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and development of ASK1 inhibitors.
Reginald Brys, Karl Gibson, Tanja Poljak, Steven Van Der Plas, David Amantini

Prog Med Chem· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stereocontrolled synthesis of 5-azaspiro[2.3]hexane derivatives as conformationally "frozen" analogues of L-glutamic acid.
Beatrice Bechi, David Amantini, Cristina Tintori, Maurizio Botta, Romano di Fabio

Beilstein J Org Chem· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of 1,2,4-triazines and the triazinoisoquinolinedione DEF ring system of noelaquinone.
Liming Cao, John P Maciejewski, Stephan Elzner, David Amantini, Peter Wipf

Org Biomol Chem· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists.
Alessandro Gozzi, Giuliano Turrini, Laura Piccoli, Mario Massagrande, David Amantini

PLoS One· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of 4-aryl-1H-1,2,3-triazoles through TBAF-catalyzed [3 + 2] cycloaddition of 2-aryl-1-nitroethenes with TMSN3 under solvent-free conditions.
David Amantini, Francesco Fringuelli, Oriana Piermatti, Ferdinando Pizzo, Ennio Zunino

J Org Chem· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TBAF-catalyzed synthesis of 5-substituted 1H-tetrazoles under solventless conditions.
David Amantini, Romina Beleggia, Francesco Fringuelli, Ferdinando Pizzo, Luigi Vaccaro

J Org Chem· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3-nitrocoumarins as dienophiles in the Diels-Alder reaction in water. An approach to the synthesis of nitrotetrahydrobenzo[c]chromenones and dihydrodibenzo[b,d]furans.
David Amantini, Francesco Fringuelli, Oriana Piermatti, Ferdinando Pizzo, Luigi Vaccaro

J Org Chem· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uncatalyzed [4 + 2] cycloadditions of 3-nitrocoumarins with vinyl ethers in solventless conditions. A new entry to chromene derivatives.
David Amantini, Francesco Fringuelli, Ferdinando Pizzo

J Org Chem· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis